Nektar Therapeutics (NASDAQ:NKTR) Stock Rating Upgraded by Oppenheimer
Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) was upgraded by equities research analysts at Oppenheimer from a “market perform” rating to an “outperform” rating in a research report issued on Friday, Marketbeat Ratings reports. The brokerage currently has a $6.00 target price on the biopharmaceutical company’s stock. NKTR has been the subject of a number […]
Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) was upgraded by equities research analysts at Oppenheimer from a “market perform” rating to an “outperform” rating in a research report issued on Friday, Marketbeat Ratings reports. The brokerage currently has a $6.00 target price on the biopharmaceutical company’s stock. NKTR has been the subject of a number […]
